Ventrus Biosciences (VTUS +5.3%) moves higher today, offsetting some of the losses from a lower than expected Q3 EPS yesterday. Cantor Fitzgerald thinks the results were "meaningless" and the stock is extremely undervalued. The firm believes the market is too deeply discounting the company's diltiazem hydrochloride cream, a treatment for anal fissures currently in Phase 3 testing. The drug suffered a setback recently when the FDA said it required a second Phase 3 study, but Cantor believes it should be market ready by the end of 2014.
Ventrus Biosciences (VTUS +5.3%) moves higher today, offsetting some of the losses from a lower...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs